
No results matched your search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
GILD | NASDAQ | USD | Real-time | |
GILD | Mexico | MXN | Delayed | |
GILD | Switzerland | CHF | Delayed | |
GILDUSD | Switzerland | USD | Delayed | |
GILD | Frankfurt | EUR | Delayed | |
GILD | Berlin | EUR | Delayed | |
GILD | TradeGate | EUR | Delayed | |
GILD | Munich | EUR | Delayed | |
GILD | Xetra | EUR | Delayed | |
GILD | Stuttgart | EUR | Delayed | |
GILD | Vienna | EUR | Delayed |
By Takashi Umekawa TOKYO (Reuters) - Japanese doctor Yasushi Goto remembers prescribing the cancer drug Opdivo to an octogenarian and wondering whether taxpayers might object to...
Two big biotech stocks. One clear winner.
Currently, the company pays a yearly dividend of 2.52 USD, which equals a yield of 3.85%.
For Immediate ReleaseChicago, IL –February 21, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts...
As we approach the tail end of earnings results, regular pipeline updates and data read outs take centerstage in the biotech sector. Key among those include Intercept...
Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) rose about 6.1% after the company announced positive top-line results from its pivotal phase III REGENERATE study of...
Type | 5 mins | 15 mins | Hourly | Daily | Monthly |
---|---|---|---|---|---|
Moving Averages | Buy | Sell | Sell | Strong Sell | Sell |
Technical Indicators | Strong Buy | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Summary | Strong Buy | Strong Sell | Strong Sell | Strong Sell | Strong Sell |
Filter Table By:
Pattern | Timeframe | Reliability | Candles Ago | Candle Time | |
---|---|---|---|---|---|
Emerging Patterns | |||||
Harami Bullish | 1D | Current | |||
Completed Patterns | |||||
Three Outside Up | 15 | 2 | Feb 22, 2019 03:15PM | ||
Bullish Engulfing | 15 | 3 | Feb 22, 2019 03:00PM | ||
Engulfing Bearish | 1M | 4 | Oct 18 |
Exchange | Last | Bid | Ask | Volume | Change % | Currency | Time | ||
---|---|---|---|---|---|---|---|---|---|
NASDAQ | 65.74 | 65.58 | 65.90 | 4,925,489 | +0.29% | USD | 22/02 | ||
Mexico | 1,273.90 | 0.00 | 0.00 | 0 | 0.00% | MXN | 21/02 | ||
Switzerland | 66.000 | 0.000 | 0.000 | 0 | +0.00% | CHF | 14/02 | ||
Switzerland | 67.000 | 0.000 | 0.000 | 0 | 0.00% | USD | 05/02 | ||
Frankfurt | 58.04 | 57.96 | 58.03 | 2,201 | -0.27% | EUR | 22/02 | ||
Berlin | 57.800 | 57.970 | 58.010 | 50 | -2.22% | EUR | 22/02 | ||
TradeGate | 57.81 | 57.96 | 58.08 | 3,104 | +0.16% | EUR | 22/02 | ||
Munich | 57.740 | 0.000 | 0.000 | 0 | -2.27% | EUR | 22/02 | ||
Xetra | 58.1000 | 57.7500 | 58.4100 | 3,442 | -0.02% | EUR | 22/02 | ||
Stuttgart | 58.070 | 0.000 | 0.000 | 242 | +0.10% | EUR | 22/02 | ||
Vienna | 58.070 | 64.960 | 66.780 | 0 | -1.81% | EUR | 21/02 |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
---|---|---|---|---|---|---|---|---|---|
Apple | 172.97 | 173.00 | 171.38 | +1.91 | +1.12% | 18.91M | 22/02 | ||
Alphabet A | 1,116.56 | 1,117.25 | 1,100.50 | +12.35 | +1.12% | 1.47M | 22/02 | ||
161.89 | 162.41 | 160.31 | +1.85 | +1.16% | 15.86M | 22/02 | |||
Amazon.com | 1,631.56 | 1,634.94 | 1,621.17 | +12.12 | +0.75% | 3.10M | 22/02 | ||
Vale ADR | 12.500 | 12.510 | 12.170 | +0.470 | +3.91% | 20.25M | 22/02 | ||
Petroleo Brasileiro Petrobras ADR | 16.63 | 16.75 | 16.53 | -0.02 | -0.12% | 11.55M | 22/02 | ||
Cleveland-Cliffs | 11.580 | 11.640 | 11.420 | +0.070 | +0.61% | 5.61M | 22/02 | ||
Alibaba | 176.92 | 177.02 | 172.52 | +5.26 | +3.06% | 16.18M | 22/02 | ||
Kraft Heinz | 34.95 | 36.00 | 34.51 | -13.23 | -27.46% | 135.20M | 22/02 | ||
Boeing | 424.05 | 424.47 | 419.14 | +6.47 | +1.55% | 3.13M | 22/02 |
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.
Read MoreBrokers | Regulation | Minimum Deposit | |
---|---|---|---|
![]() |
U.S. Commodity Futures Trading Commission (United States), Securities and Exchange Commission (United States) | $0 | Start Trading |
![]() |
U.S. Commodity Futures Trading Commission (United States) | Start Trading | |
![]() |
U.S. Commodity Futures Trading Commission (United States) | $250 | Start Trading |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review